menu
    • menu
    [{"orgOrder":0,"company":"Akamis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||CD40","graph1":"Oncology","graph2":"Phase I","graph3":"Akamis Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akamis Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Akamis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Akamis Bio","sponsor":"Bluebird Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"NG-347","moa":"||EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Akamis Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akamis Bio \/ Bluebird Bio","highestDevelopmentStatusID":"5","companyTruncated":"Akamis Bio \/ Bluebird Bio"},{"orgOrder":0,"company":"Akamis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"NG-641","moa":"AP\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Akamis Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Akamis Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Akamis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Akamis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"NG-350A","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Akamis Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akamis Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Akamis Bio \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by PsiOxus Therapeutics

    Menu

    PsiOxus Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Akamis Bio

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed

                            Akamis Bio

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NG-350A,Capecitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Akamis Begins Phase 1b FORTRESS Trial for Rectal Cancer Therapy

                            Details : NG-350A is a CD40 agonist gene therapy candidate, which is currenty being evaluated for the treatment of locally advanced rectal cancer.

                            Product Name : NG-350A

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            April 03, 2025

                            Lead Product(s) : NG-350A,Capecitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Akamis Bio

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed

                            Akamis Bio

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NG-350A

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : $30.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Akamis Bio Announces $30 Million Financing, Provides Clinical Program Update and Relaunches with Name Change f...

                            Details : The net proceeds will fund development activities for the clinical stage NG-350A and NG-641 programs, as well as general corporate purposes. NG-350A is oncolytic adenoviral vector which expresses a full length agonist anti-CD40 antibody at the site of vi...

                            Product Name : NG-350A

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            June 01, 2023

                            Lead Product(s) : NG-350A

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : $30.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Akamis Bio

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed

                            Akamis Bio

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,NG-347,NG-641

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Bluebird Bio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PsiOxus and Bluebird Bio Present Novel Data Combining PsiOxus T-SIGn Platform with CAR-T Therapy to Clear Prim...

                            Details : The study showed that when injected intravenously into mice with established human tumor xenografts, PsiOxus’ armed T-SIGn vectors reprogrammed the tumor microenvironment to a proinflammatory state.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 14, 2021

                            Lead Product(s) : Undisclosed,NG-347,NG-641

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Bluebird Bio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Akamis Bio

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed

                            Akamis Bio

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NG-641

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PsiOxus Therapeutics Announces Clinical Trial with Third Cancer Gene Therapy Treatment

                            Details : This is the first time that a tumor-specific virus containing four different therapeutic transgenes has been administered to cancer patients.

                            Product Name : NG-641

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            May 03, 2020

                            Lead Product(s) : NG-641

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth